Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma

Area of Science:

• Neuro-oncology
• Cancer Therapeutics
• Malignant Neoplasms

Background:

• Surgical resection is the primary glioblastoma (GBM) treatment, but effective therapies are limited by tumor heterogeneity and microenvironment.
• Current FDA-approved agents, temozolomide and bevacizumab, show limited efficacy and do not prolong overall survival.
• High therapeutic resistance necessitates urgent development of novel agents for GBM.

Purpose of the Study:

• To review current and novel therapeutic strategies for glioblastoma (GBM).
• To highlight promising solutions for overcoming therapeutic failures in GBM treatment.
• To discuss the application of emerging therapies in clinical trials for GBM.

Main Methods:

• Review of preclinical and clinical data on glioblastoma (GBM) therapeutics.
• Analysis of clinical trials investigating immune checkpoint inhibition, CAR T-cell therapy, virotherapies, and tumor vaccination.
• Synthesis of information on current and novel therapeutic agents for GBM.

Main Results:

• Glioblastoma (GBM) exhibits significant heterogeneity, complicating treatment development.
• Existing therapies like temozolomide and bevacizumab have limitations in efficacy and survival benefit.
• Emerging therapies including immunotherapy, virotherapy, and vaccination are under active clinical investigation for GBM.

Conclusions:

• Novel therapeutic approaches are crucial for overcoming glioblastoma (GBM) resistance.
• Immunotherapy, virotherapy, and tumor vaccination represent promising avenues for GBM treatment.
• Ongoing clinical trials are essential for evaluating the efficacy of these novel agents in GBM.